Schistosomiasis
diseaseOn this page
Also known as Bilharziabilharziasissnail fever
Summary
Schistosomiasis (MONDO:0015254) is a disease (an umbrella term covering 7 Mondo subtypes) and 54 clinical trials. Top therapeutic interventions include praziquantel, amodiaquine, and albendazole. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe)
- Umbrella term: 7 Mondo subtypes
- Clinical trials: 54
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | <1 / 1 000 000 | Europe | Not yet validated | |
| Point prevalence | >1 / 1000 | Africa | Not yet validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | schistosomiasis |
| Mondo ID | MONDO:0015254 |
| EFO | EFO:1001475 |
| MeSH | D012552 |
| Orphanet | 1247 |
| DOID | DOID:1395 |
| ICD-10-CM | B65 |
| ICD-11 | 1194562592 |
| NCIT | C35000 |
| SNOMED CT | 10087007 |
| UMLS | C0036323 |
| MedGen | 48573 |
| GARD | 0009687 |
| MedDRA | 10039603 |
| Is cancer (heuristic) | no |
Also known as: Bilharzia · bilharziasis · schistosomiasis · snail fever
Disease family
This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › schistosomiasis
Related subtypes (21): acanthocephaliasis, heterophyiasis, metagonimiasis, fascioliasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, filariasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease
Subtypes (7): cercarial dermatitis, neuroschistosomiasis, urinary schistosomiasis, intestinal schistosomiasis, Schistosoma japonicum infectious disease, Schistosoma mansoni infectious disease, Schistosoma intercalatum infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Praziquantel | Approved (phase 4) |
| Artesunate | Phase 3 (in late-stage trials) |
| Praziquantel, (R)- | Phase 3 (in late-stage trials) |
| Pyrimethamine | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 54.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 33 |
| PHASE2 | 7 |
| PHASE1 | 7 |
| PHASE3 | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01459146 | PHASE4 | UNKNOWN | Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana |
| NCT02734186 | PHASE4 | WITHDRAWN | Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis |
| NCT01558336 | PHASE3 | COMPLETED | Schistosoma Haematobium Infections and Praziquantel |
| NCT02868385 | PHASE3 | COMPLETED | Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) |
| NCT03845140 | PHASE3 | COMPLETED | L-PZQ ODT in Schistosoma Infected Children |
| NCT04115072 | PHASE2/PHASE3 | COMPLETED | Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study |
| NCT00486863 | PHASE2 | COMPLETED | S. Japonicum and Pregnancy Outcomes |
| NCT02806232 | PHASE2 | COMPLETED | An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) |
| NCT03041766 | PHASE2 | COMPLETED | Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions |
| NCT03640377 | PHASE2 | COMPLETED | Praziquantel in Children Under Age 4 |
| NCT03799510 | PHASE2 | COMPLETED | Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children |
| NCT03910972 | PHASE1/PHASE2 | COMPLETED | Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults |
| NCT04589390 | PHASE2 | UNKNOWN | Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension |
| NCT05999825 | PHASE2 | UNKNOWN | Sm-p80 Schistosomiasis Challenge Study |
| NCT01154049 | PHASE1 | COMPLETED | Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis |
| NCT01288872 | PHASE1 | COMPLETED | Praziquantel-Pharmacokinetic Study |
| NCT01512277 | PHASE1 | COMPLETED | Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis |
| NCT02337855 | PHASE1 | COMPLETED | A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults |
| NCT03110757 | PHASE1 | COMPLETED | A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults |
| NCT05292391 | PHASE1 | COMPLETED | Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults |
| NCT05762393 | PHASE1 | COMPLETED | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar |
| NCT06560853 | Not specified | ACTIVE_NOT_RECRUITING | Evaluation of a Comprehensive School Health Programme in Zambia |
| NCT06698510 | Not specified | RECRUITING | Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study |
| NCT06828536 | Not specified | NOT_YET_RECRUITING | Female Genital Schistosomiasis in Migrant Women: A Pilot Study |
| NCT06873308 | Not specified | RECRUITING | Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis |
| NCT07358910 | Not specified | RECRUITING | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
| NCT07482215 | Not specified | NOT_YET_RECRUITING | Prevalence and Molecular Identification of Human Schistosomiasis |
| NCT00215267 | Not specified | COMPLETED | The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda |
| NCT00276224 | Not specified | COMPLETED | Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia |
| NCT00463528 | Not specified | COMPLETED | Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso |
| NCT00463593 | Not specified | COMPLETED | Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes |
| NCT00463632 | Not specified | COMPLETED | Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control |
| NCT00463931 | Not specified | COMPLETED | Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana |
| NCT01214876 | Not specified | COMPLETED | Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires |
| NCT01260012 | Not specified | UNKNOWN | Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis |
| NCT01424410 | Not specified | COMPLETED | Health Benefits of Repeated Treatment in Pediatric Schistosomiasis |
| NCT01553552 | Not specified | COMPLETED | Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal |
| NCT01869465 | Not specified | UNKNOWN | Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis |
| NCT02105714 | Not specified | COMPLETED | Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders |
| NCT02144389 | Not specified | COMPLETED | Arachidonic Acid Treatment Against Schistosomiasis Infection in Children |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PRAZIQUANTEL | 4 | 10 |
| AMODIAQUINE | 4 | 6 |
| ALBENDAZOLE | 4 | 1 |
| PYRIMETHAMINE | 4 | 1 |
| SELEXIPAG | 4 | 1 |
| SULFADOXINE | 4 | 1 |
| GLA-AF | 2 | 2 |
| CHEMBL3264245 | 0 | 10 |
Related Atlas pages
- Drugs: Praziquantel, Amodiaquine, Albendazole, Pyrimethamine, Selexipag, Sulfadoxine